drugset / Trial / NCT05366829
Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma
Phase 2
Recruiting
35 enrolled
Rutgers, The State University of New Jersey
BioGene Pharmaceutical Ltd. · collabNatera, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The investigators hypothesize that the addition of Tislelizumab after definitive local therapy for locally advanced inoperable Hepatocellular carcinoma (HCC) will synergize with local therapy as well as treat micro metastatic disease and improve one year progression-free survival rates for participants and optimize local control.
Timeline
- Start
- 2022-07-25
- Primary completion
- 2027-06-01
- Completion
- 2027-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tislelizumab | Monoclonal antibody | — | — |